Lipoprotein-associated phospholipase A2 (Lp-PLA), an enzyme associated with inflammation, is used as a biomarker for cardiovascular disease risk. Both the concentration and activity of Lp-PLA have been shown to be clinically relevant. However, there is a discordance between the serum concentration of Lp-PLA measured by the standard ELISA-based immunoassays and the activity of this enzyme, leading to substantial discordance in risk categorization depending on assay format.
Lipoprotein-associated phospholipase A2 (Lp-PLA), an enzyme associated with inflammation, is used as a biomarker for cardiovascular disease risk. Both the concentration and activity of Lp-PLA have been shown to be clinically relevant. However, there is a discordance between the serum concentration of Lp-PLA measured by the standard ELISA-based immunoassays and the activity of this enzyme, leading to substantial discordance in risk categorization depending on assay format.